Key Points
The therapy uses our bodys immune cells, called T-cells, a type of lymphocyte or white blood cell...
T-cells can grow into different types of mature T-cells..
The therapy involves taking out T-cells from a patients body, genetically editing them to recognise cancerous cells as foreign bodies that need to be removed, and putting them back into the patients body...
The modified CAR T-cells perform both helper T-cell and killer T-cell functions, i.e., the activating and antigen-binding functions, with the same receptor...
The IIT Bombay centre is expected to treat patients with relapsed-refractory B-cell lymphoma and leukaemia.The DGCIapproved the therapy, called the NexCAR19, in October...
You might be interested in
All about India's 1st 'living drug' that uses patient's own genetically engineered cells to fight cancer
16, Oct, 23Patients already registering for CAR T-cell therapy, developed indigenously by ImmunoACT under the name NexCAR19. It will be used to treat leukemia & refractory or relapsed lymphoma.
NexCAR 19 cancer therapy: Conceived at IIT Bombay, delivered in Tata Memorial
10, Mar, 24CAR T-cell therapy involves modifying a patient’s T-cells—white blood cells that are integral to the immune system. The lab-modified cells are then infused in the patient to multiply and fight cancerous cells. The therapy costs $400,000 in the US and tenth of that in India. But, does it work?